Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $66 at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $66 at RBC Capital

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

November 12, 2024 4:05 PM EST

Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 millionAchieved positive topline trial results from pivotal trial with troriluzole in spinocerebellar ataxia (SCA)Troriluzole 200 mg QD dosed orally in patients with SCA met the study's primary endpoint on the change from baseline on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypesStatistically significant superiority achieved on 9 consecutive, prespecified primary and secondary endpointsBoth the study protocol and... More